Roivant Sciences Ltd. $ROIV Shares Purchased by HighVista Strategies LLC

HighVista Strategies LLC grew its stake in shares of Roivant Sciences Ltd. (NASDAQ:ROIV) by 61.4% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 98,858 shares of the company’s stock after purchasing an additional 37,590 shares during the quarter. HighVista Strategies LLC’s holdings in Roivant Sciences were worth $1,496,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. Penn Davis Mcfarland Inc. boosted its holdings in shares of Roivant Sciences by 10.1% during the third quarter. Penn Davis Mcfarland Inc. now owns 1,862,088 shares of the company’s stock valued at $28,173,000 after acquiring an additional 170,456 shares during the period. Valeo Financial Advisors LLC bought a new stake in shares of Roivant Sciences during the second quarter valued at approximately $1,145,000. TD Asset Management Inc boosted its position in shares of Roivant Sciences by 94.7% during the third quarter. TD Asset Management Inc now owns 316,200 shares of the company’s stock worth $4,784,000 after buying an additional 153,800 shares during the period. New York State Common Retirement Fund grew its holdings in Roivant Sciences by 25.4% in the 3rd quarter. New York State Common Retirement Fund now owns 229,037 shares of the company’s stock worth $3,465,000 after buying an additional 46,344 shares in the last quarter. Finally, Franklin Resources Inc. acquired a new stake in Roivant Sciences in the 2nd quarter valued at approximately $997,000. 64.76% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on ROIV shares. Guggenheim lifted their price objective on shares of Roivant Sciences from $28.00 to $30.00 and gave the company a “buy” rating in a research note on Monday, February 9th. Jefferies Financial Group reissued a “buy” rating on shares of Roivant Sciences in a report on Tuesday, March 3rd. Leerink Partners lifted their price target on Roivant Sciences from $29.00 to $32.00 and gave the company an “outperform” rating in a research report on Monday, December 15th. HC Wainwright upped their price objective on Roivant Sciences from $33.00 to $34.00 and gave the company a “buy” rating in a report on Wednesday, March 4th. Finally, Citigroup raised their price objective on shares of Roivant Sciences from $26.00 to $35.00 and gave the company a “buy” rating in a research report on Tuesday, February 10th. Eight analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $28.81.

Roivant Sciences Stock Performance

Shares of NASDAQ:ROIV opened at $28.06 on Monday. Roivant Sciences Ltd. has a 52 week low of $8.73 and a 52 week high of $30.33. The company has a market cap of $20.08 billion, a PE ratio of -23.98 and a beta of 1.17. The firm has a 50 day simple moving average of $25.29 and a 200 day simple moving average of $20.76.

Insiders Place Their Bets

In other Roivant Sciences news, CEO Eric Venker sold 200,000 shares of Roivant Sciences stock in a transaction dated Friday, February 13th. The stock was sold at an average price of $26.49, for a total transaction of $5,298,000.00. Following the transaction, the chief executive officer owned 1,654,597 shares of the company’s stock, valued at $43,830,274.53. The trade was a 10.78% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Daniel Allen Gold sold 375,784 shares of the stock in a transaction that occurred on Friday, February 13th. The stock was sold at an average price of $26.50, for a total transaction of $9,958,276.00. Following the completion of the sale, the director directly owned 15,127,329 shares of the company’s stock, valued at $400,874,218.50. This trade represents a 2.42% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 8,274,269 shares of company stock valued at $205,891,471 in the last 90 days. Insiders own 10.80% of the company’s stock.

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.